Abstract: Tuberaria lignosa (Sweet) Samp. is found in European regions, and has antioxidant properties due to its composition in ascorbic acid and phenolic compounds. Given its traditional use and antioxidant properties, the tumor cell growth inhibitory potential of aqueous extracts from T. lignosa (prepared by infusion and decoction) was investigated in three human tumor cell lines: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and HCT-15 (human colorectal adenocarcinoma). Both extracts inhibited the growth of these cell lines; the most potent one being the T. lignosa extract obtained by infusion in the NCI-H460 cells (GI 50 of approximately 50 µg/mL). Further assays were carried out with this extract in NCI-H460 cells. At 100 µg/mL or 150 µg/mL it caused an increase in the percentage of cells in the G0/G1 phase and a decrease of cells in S phase of the cell cycle. Additionally, these concentrations caused an increase in the percentage of apoptotic cells. In agreement, a decrease in total poly (ADP-ribose) polymerase (PARP) and pro-caspase 3 levels was found. In conclusion, the T. lignosa extract obtained by infusion was more potent in NCI-H460 cells, altering the cell cycle progression and inducing apoptosis. This work highlights the importance of T. lignosa as a source of bioactive compounds with tumor cell growth inhibitory potential.
Introduction
Herbal drugs have been extensively used for the treatment of several diseases all over the world [1] [2] [3] . In particular, the interest in plants as a natural source of pharmaceutical compounds with antitumor activity has increased in the past years. Indeed, several anti-cancer agents derived from plants (such as vinca alkaloids, epipodophyllotoxins derivatives, taxanes, and the campothecin derivatives) have been discovered in the last decades [1, 2, [4] [5] [6] [7] [8] [9] . Furthermore, several plant-derived anticancer agents have achieved pre-clinical or clinical development [7, 8, 10, 11] .
Tuberaria lignosa (Sweet) Samp. (Rockrose like species) is a plant found in the west and south part of Europe and is mostly present in the Iberian Peninsula, where it is known as "alcária" or "erva loba" [12, 13] . This plant has been used in traditional medicine to treat several diseases, such as gastrointestinal disorders, viral infections, and skin infections, among others [12, 13] . The preparation of medicinal infusions and decoctions may involve the use of the whole plant or just some parts of the plant and may be prepared fresh or shade-dried [12] . The chemical composition of T. lignosa aqueous extracts, obtained by infusion and decoction, has been previously analyzed and compared by some of the authors [12, 13] . It has been demonstrated that infusions obtained from freeze-dried samples have higher concentrations in compounds such as free sugars (e.g., fructose, glucose, sucrose, trehalose, and raffinose) and lower concentrations of ascorbic acid and phenolic compounds (including ellagic acid derivatives and flavonoids) when compared with decoctions obtained from freeze-dried samples and infusions prepared from shade-dried samples [12] . Additionally, the freeze-dried samples also proved to have higher antioxidant activity than the other samples and even higher than trolox, the positive control used in the referred study [12] . Both infusion and decoction samples from T. lignosa have bioactive molecules, such as phenolic compounds and ascorbic acid, which can explain their antioxidant activity [12] [13] [14] [15] .
In spite of its content in such bioactive molecules, to our knowledge the tumor cell growth inhibitory potential of this plant has never been studied. Therefore, the main objective of this work was to investigate the tumor cell growth inhibitory effect of two aqueous extracts prepared by infusion and decoction from Tuberaria lignosa in different human tumor cell lines: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and HCT-15 (human colorectal adenocarcinoma). In addition, the cellular effects of the T. lignosa extract obtained by infusion on cell cycle profile and apoptosis were studied in more detail in the most sensitive cell line (NCI-H460).
Results and Discussion

T. lignosa Extracts Inhibited Tumor Cell Growth
The sulforhodamine B (SRB) assay was carried out in order to determinate the in vitro cytotoxicity of the T. lignosa aqueous extracts, prepared by decoction and infusion, in three different human tumor cell lines, using doxorubicin as the positive control. The results showed that T. lignosa extract obtained by infusion was the most potent extract in the MCF-7 and in the NCI-H460 cells (Table 1) . However, in the HCT-15 cells both extracts had similar effect. Overall, the most potent extract was the infusion of T. lignosa in the NCI-H460 cells. This is probably due to the different chemical composition of the extracts, namely in phenolic acid derivatives, ellagic acid derivatives, and flavonoids, with infusion presenting higher content in phenolic acid derivatives [12] . Therefore, the following analyses were conducted with this extract (infusion). The cell line selected to continue the studies was the NCI-H460, since this was the cell line in which the infusion extract was more potent and since it is representative of lung cancer which has high incidence and is still one of the most common cause of cancer related deaths [16] . The compounds isolated from plants with potential activity against cancer have shown multiple mechanisms of action, such as interference with death signals thereby inducing apoptosis, disturbance of multiple cellular signaling pathways, regulation of the cell cycle, and/or interference with cellular invasion and metastasis [3, [17] [18] [19] [20] [21] . For this reason, this study has further investigated the effect of the infusion extract of T. lignosa on cell cycle and apoptosis.
T. lignosa Infusion Extract Blocked the Cell Cycle Progression of NCI-H460 Cells
To gain insight into the cytotoxic mechanism of action of the T. lignosa extract obtained by infusion, its effect on the cell cycle was analyzed. For this, to assess a possible dose-dependent effect, NCI-H460 cells were treated with increasing concentrations of the extract: 50 µg/mL, 100 µg/mL, and 150 µg/mL (approximately the GI 50 , 2ˆGI 50, and 3ˆGI 50 concentrations, respectively, with GI referring to the concentration that inhibits 50% of net cell growth). Controls for the solvent of the extract (H 2 O) were included. Results showed that treatment of the NCI-H460 cells with the highest tested concentrations (100 µg/mL or 150 µg/mL) of the extract caused a statistically significant increase in the percentage of cells in the G0/G1 phase of the cell cycle and a statistically significant decrease in the percentage of the cells in the S phase of the cell cycle ( Figure 1 ). In addition, for the 100 µg/mL concentration a statistically significant decrease in the G2/M phase of the cell cycle was also observed. This data suggested that T. lignosa infusion extract blocked the cell cycle progression of the NCI-H460 cells, having a significant effect at 100 µg/mL and 150 µg/mL. The compounds isolated from plants with potential activity against cancer have shown multiple mechanisms of action, such as interference with death signals thereby inducing apoptosis, disturbance of multiple cellular signaling pathways, regulation of the cell cycle, and/or interference with cellular invasion and metastasis [3, [17] [18] [19] [20] [21] . For this reason, this study has further investigated the effect of the infusion extract of T. lignosa on cell cycle and apoptosis.
To gain insight into the cytotoxic mechanism of action of the T. lignosa extract obtained by infusion, its effect on the cell cycle was analyzed. For this, to assess a possible dose-dependent effect, NCI-H460 cells were treated with increasing concentrations of the extract: 50 μg/mL, 100 μg/mL, and 150 μg/mL (approximately the GI50, 2 × GI50, and 3 × GI50 concentrations, respectively, with GI referring to the concentration that inhibits 50% of net cell growth). Controls for the solvent of the extract (H2O) were included. Results showed that treatment of the NCI-H460 cells with the highest tested concentrations (100 μg/mL or 150 μg/mL) of the extract caused a statistically significant increase in the percentage of cells in the G0/G1 phase of the cell cycle and a statistically significant decrease in the percentage of the cells in the S phase of the cell cycle ( Figure 1 ). In addition, for the 100 μg/mL concentration a statistically significant decrease in the G2/M phase of the cell cycle was also observed. This data suggested that T. lignosa infusion extract blocked the cell cycle progression of the NCI-H460 cells, having a significant effect at 100 μg/mL and 150 μg/mL. Various plant extracts with recognized antitumor activity have similar effects, arresting cells in the G0/G1 phase of the cell cycle, such as ginseng extract [22] , the extract of Tinospora cordifolia [23] , or the Marsdenia tenacissima extract [24] .
T. lignosa Infusion Extract Induced Apoptosis in NCI-H460 Cells
The effect of T. lignosa infusion extract on cellular apoptosis was also analyzed by flow cytometry analysis of Annexin V-FITC and propidium iodide (PI) labeling/staining. Results (Table 2) showed an increase in the percentage of cells undergoing apoptosis after treatment with the extract, with statistically significant results observed for the 150 μg/mL concentration treatment. Treatment of cells with 100 μg/mL of extract also caused an increase in apoptosis to nearly twice the control levels, even though this increase was not considered statistically significant. The reason why cellular treatment with 100 μg/mL of extract caused statistically significant alterations in cell cycle but not in apoptosis Various plant extracts with recognized antitumor activity have similar effects, arresting cells in the G0/G1 phase of the cell cycle, such as ginseng extract [22] , the extract of Tinospora cordifolia [23] , or the Marsdenia tenacissima extract [24] .
The effect of T. lignosa infusion extract on cellular apoptosis was also analyzed by flow cytometry analysis of Annexin V-FITC and propidium iodide (PI) labeling/staining. Results (Table 2) showed an increase in the percentage of cells undergoing apoptosis after treatment with the extract, with statistically significant results observed for the 150 µg/mL concentration treatment. Treatment of cells with 100 µg/mL of extract also caused an increase in apoptosis to nearly twice the control levels, even though this increase was not considered statistically significant. The reason why cellular treatment with 100 µg/mL of extract caused statistically significant alterations in cell cycle but not in apoptosis is possibly because the effect on the cell cycle might precede the effect on apoptosis. Time-course experiments would confirm this hypothesis. Nevertheless, overall this data demonstrated that this extract caused apoptosis in NCI-H460 cells. To confirm the effect on apoptosis, the effect of this extract on the expression levels of cellular proteins involved in apoptosis was analyzed. Results from the Western blot analysis showed a decrease in the levels of total poly (ADP-ribose) polymerase (PARP) and pro-caspase 3 ( Figure 2 ). These results further confirm that the T. lignosa infusion extract induced apoptosis in NCI-H460 cells. Indeed, a reduction in the total levels of PARP is an accepted event in cellular apoptosis [25, 26] . Unfortunately, our antibody does not detect the cleaved form of caspase-3. However, the observed reduction in pro-caspase 3 is indicative that the extract induced the intrinsic pathway of apoptosis [27, 28] . To confirm the effect on apoptosis, the effect of this extract on the expression levels of cellular proteins involved in apoptosis was analyzed. Results from the Western blot analysis showed a decrease in the levels of total poly (ADP-ribose) polymerase (PARP) and pro-caspase 3 ( Figure 2 ). These results further confirm that the T. lignosa infusion extract induced apoptosis in NCI-H460 cells. Indeed, a reduction in the total levels of PARP is an accepted event in cellular apoptosis [25, 26] . Unfortunately, our antibody does not detect the cleaved form of caspase-3. However, the observed reduction in pro-caspase 3 is indicative that the extract induced the intrinsic pathway of apoptosis [27, 28] . 
Material and Methods
Samples and Preparation of the T. lignosa Extracts
T. lignosa was collected in Miranda do Douro (Trás-os-Montes, Northeastern Portugal), as referred in Pinela et al., 2012 [12] . The preparation of decoctions and infusions followed the protocol previously described by Pinela et al., 2012 [12] . Stock solutions of the extract were prepared in water and stored at −20 °C. Both aqueous extracts were previously characterized by some of the authors in terms of phenolic compounds [12] . 
Material and Methods
Samples and Preparation of the T. lignosa Extracts
T. lignosa was collected in Miranda do Douro (Trás-os-Montes, Northeastern Portugal), as referred in Pinela et al., 2012 [12] . The preparation of decoctions and infusions followed the protocol previously described by Pinela et al., 2012 [12] . Stock solutions of the extract were prepared in water and stored at´20˝C. Both aqueous extracts were previously characterized by some of the authors in terms of phenolic compounds [12] .
Cell Culture
Three different human tumor cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and HCT-15 (human colorectal adenocarcinoma). All of these cells were maintained in RPMI-1640 medium with Glutamax™, supplemented with 1 M 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) buffer and fetal bovine serum (FBS). The FBS concentration used was 5% for the cell growth inhibition assay and 10% for the remaining assays. The monolayer cultures were kept at 37˝C in a humidified incubator with 5% CO 2 . Cells were routinely observed with a microscope (Nikon eclipse TS100 microscope, Nikon Instruments Europe BV, Amsterdam, The Netherlands). All the experiments described were performed only when exponentially growing cells presented more than 90% viability.
Cell Growth Inhibition Assay
The SRB assay was adapted from the procedure used in the NCI's in vitro anti-cancer drug screening [29, 30] . Briefly, cells were plated in 96-well plates at their previously determined optimal concentrations (5.0ˆ10 4 cells/mL for NCI-H460 and MCF-7 cells and 1.0ˆ10 5 cells/mL for HCT-15 cells) and incubated for 24 h. Cells were then treated with five serial dilutions of T. lignosa infusion and T. lignosa decoction, ranging from 400 µg/mL to 25 µg/mL. Doxorubicin was used as a positive control (ranging from 150 nM to 9.37 nM). The effect of the solvent of the extracts (water) on the growth of the cell lines was also evaluated by treating cells with the maximum concentration of water used. Following 48 h incubation with the extract, plates were fixed by adding ice-cold 10% ice cold trichloroacetic acid (TCA) (w/v, final concentration, Panreac, Barcelona, Spain) and stained with 1% SRB (Sigma Aldrich, St. Louis, MO, USA) in 1% (v/v) acetic acid. Bound dye was solubilized by adding 10 mM Tris base solution (Sigma Aldrich) and finally the absorbance was measured at 510 nm in a microplate reader (BioTek ® Synergy HT, Winooski, VT, USA). Using the SRB assay, the GI 50 concentration (concentration that inhibits 50% of net cell growth) was determined for T. lignosa infusion and decoction extracts in each cell line.
Preparation of Cells for Other Analyses
For the analysis of the cell cycle, apoptosis, or Western blot, the NCI-H460 cells were plated at 1.5ˆ10 5 cells/well in-well plates and incubated for 24 h. Cells were then treated with different concentrations of the T. lignosa infusion extract: 50 µg/mL (approximately the GI 50 concentration), 100 µg/mL (approximately twice the GI 50 ), and/or 150 µg/mL (approximately three times the GI 50 ). Blank cells (treated with medium) and Control cells (treated with a concentration of water corresponding to the treatment with 100 µg/mL-Control 1, or 150 µg/mL-Control 2) were also included. After treatment, cells were trypsinized and centrifuged at 1200 rpm for 5 min. Cells were then processed according to the procedures described below.
Analysis of Cell Cycle Profile
Cells were washed in PBS, fixed with ice-cold 70% ethanol, and stored at 4˝C for at least 12 h. Next, the cells were centrifuged (5 min at 1200 rpm) and the pellets were re-suspended in a solution of PBS containing 5 µg/mL propidium iodide and 0.1 mg/mL RNase A. Cellular DNA content was analyzed by flow cytometry and the percentage of cells in the G0/G1, S, and G2/M phases of the cell cycle were determined using the BD Accuri™ C6 Flow cytometer (BD Biosciences) after cell debris and aggregates exclusion and plotting at least 20,000 events per sample [31, 32] . All data was analyzed using the FlowJo software (version 7.6.5, Tree Star, Inc., Ashland, OR, USA).
Analysis of Apoptosis
For the analysis of apoptosis, cell pellets were washed and re-suspended in 1 mL of PBS. Following centrifugation, cells were processed for apoptosis analysis with the Annexin V-FITC Apoptosis Detection Kit (eBioscience) by resuspension in buffer solution, as indicated by the manufacturer. Cells were then incubated for 10 min with Human Annexin V-FICT and further incubated for 5 min with propidium iodide. Cells were analyzed by flow cytometry using the BD Accuri™ C6 Flow cytometer and respective software, plotting at least 20,000 events per sample [33, 34] 
Analysis of Protein Expression
For the analysis of protein expression, cell pellets were washed and resuspended in PBS. Cells were centrifuged and pellets were stored at´20˝C. Cell pellets were then lysed in Winman's buffer containing 1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M NaCl, and 5 mM EDTA, complemented with protease inhibitor cocktail (Roche). The total protein content was quantified using the DC™ Protein Assay kit (Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions. Protein lysate (20 µg) were loaded on 12% SDS-PAGE gel and transferred into a nitrocellulose membrane (GE Healthcare, Cleveland, OH, USA). The following primary antibodies were used: rabbit anti-PARP-1 (1:2000, sc-7150, Santa Cruz Biotechnology, Heidelberg, Germany), mouse anti-Caspase 3 (1:2000, 05-654, Merck Millipore, Darmstadt, Germany), and goat anti-actin (1:2000, sc-1616, Santa Cruz Biotechnology). The corresponding secondary antibodies were: anti-rabbit IgG-HRP, anti-mouse IgG-HRP, or anti-goat IgG-HRP (1:2000, Santa Cruz Biotechnology). The Amersham™ ECL Western Blotting Detection Reagents (GE Healthcare), the High Performance Chemiluminescence Film (GE Healthcare), and the Kodak GBX developer and fixer (Sigma) were used for signal detection [35, 36] .
Statistical Analysis
Three replicates of each aqueous extract were used. The data was statistically analyzed using the two-tailed paired Student's t-test.
Conclusions
The obtained results show that both infusion and decoction extracts from the plant T. lignosa caused reduction in the growth of three human tumor cell lines. To our knowledge, this is the first report of such an activity for this plant. The most potent effect was observed with the infusion extract in the NCI-H460 cells. The effect of this extract on these cells was due to alterations in the cell cycle profile and to induction of cellular apoptosis. Therefore, the data here presented highlights the interest of this plant as a possible source of natural bioactive compounds with tumor cell growth inhibitory potential. It would be interesting to isolate the compounds present in the infusion extract of this plant and to identify which one(s) are responsible for the observed effects in this tumor cell line. It would also be of interest to extend this study to other extracts of this plant and other cell lines.
